MetaCap

Filana Therapeutics (FLNA) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Serina Therapeutics (SER) has outperformed Filana Therapeutics (FLNA) over the past year, losing 71.9% versus a loss of 77.7%. Over five years, SER leads with a -95.6% price change compared with -98.9% for FLNA. Filana Therapeutics is the larger company by market cap ($32.3 million vs $29.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FLNA-77.66%SER-71.93%
+23%-34%-90%
Nov 21, 20251 yearNov 20, 2026
FLNA-98.79%SER-96.03%
+46%-30%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FLNA versus SER key metrics
MetricFLNASER
Share price$0.6413$1.12
Market cap$32.26M$29.76M
1-day change+14.52%-6.67%
YTD return-67.61%-41.45%
1-year return-77.66%-71.93%
5-year return-98.85%-95.64%
EPS (TTM)$-0.87$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)$-90.97M$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$3.45$4.26
52-week low$0.39$1.06
Distance from 52-week high-81.41%-73.71%
Analyst consensusnonenone
Avg. price target upside+913.57%+748.21%
Average volume2.09M68.98K
Shares outstanding50.30M26.57M
Employees1716
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

FLNA vs SER FAQ

Which is bigger, Filana Therapeutics or Serina Therapeutics?

Filana Therapeutics (FLNA) is larger, with a market capitalization of $32.26M compared with $29.76M for Serina Therapeutics (SER).

Which stock has performed better over the past year, FLNA or SER?

SER returned -71.93% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Filana Therapeutics and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons